Eli Lilly and Company Indianapolis, Indiana, United States
Background: Interstitial lung disease (ILD) is a chronic respiratory condition that result in progressive scarring of pulmonary tissue. The epidemiology of ILD is not well described, especially in pediatric patients.
Objectives: To characterize the epidemiology of ILD in the US adult and children population.
Methods: Administrative claims from Truven Health MarketScan database were used to estimate the incidence and prevalence rates of ILD in patients enrolled in the database between 2015 and 2016. Patients with new ILD events during 2016 were included in incidence, and those with any record of ILD during 2015 and 2016, which could include those with past medical history or an acute event of ILD were included in prevalence. Estimates were reported compared between adults (age ≥18 years) and children (age <18 years). The 9th and 10th versions of the International Classification of Disease diagnosis codes were used to define ILD, including codes denoting drug-induced ILD (J70.2-J70.4).
Results: During the analysis period 23,655,953 adults and 6,697,363 children were identified. Among adults 36,588 cases of ILD were observed, corresponding to prevalence rate of 0.2%. On the other hand 2,504 cases were observed among children, with prevalence rate of 0.04%. Adults had higher number of new cases of ILD compared to children (n=25,674 vs. n=1,795), with higher incidence rates (per 1,000 person-years): adults, 1.26 95%CI=1.25-1.28; children, 0.32 95%CI=0.31-0.34.
Conclusions: ILD is uncommon (frequency <1%) in adults, and rare (frequency <0.1%) in children in medically treated US population.
